Protagonist Therapeutics, Inc. (PTGX)
Healthcare • Biotechnology
StockNasdaqGMUnited StatesUS74366E1029
134.38 USD
-0.36% today Updated 12 Nov 2026 21:22
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Protagonist Therapeutics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 12 Nov 2026 21:22. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
25 Feb 2027
in 104 days · 16:00 · estimate -0.23
Last results
3.07 vs 2.66 estimated
05 Nov 2026 · Beat +15.4%
Beat the estimate
7 of 12
5 missed · 0 in line · 3 beats in a row
Average surprise
+79.8%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 16:00 | -0.23 | — | — | Upcoming |
| 05 Nov 2026 16:00 | 2.66 | 3.07 | +15.4% | Beat |
| 05 Aug 2026 16:00 | 1.93 | 2.29 | +18.7% | Beat |
| 05 May 2026 16:00 | -0.65 | 0.05 | +107.6% | Beat |
| 25 Feb 2026 16:00 | -0.54 | -0.69 | -27.4% | Miss |
| 06 Nov 2025 16:00 | -0.64 | -0.62 | +3.7% | Beat |
| 06 Aug 2025 16:00 | -0.52 | -0.55 | -4.8% | Miss |
| 06 May 2025 16:00 | 0.11 | -0.19 | -272.7% | Miss |
| 21 Feb 2025 07:00 | 0.25 | 1.98 | +692.0% | Beat |
| 07 Nov 2024 16:00 | -0.53 | -0.54 | -1.9% | Miss |
| 06 Aug 2024 07:00 | -0.41 | -0.50 | -21.1% | Miss |
| 07 May 2024 16:00 | 1.60 | 3.26 | +103.8% | Beat |
| 27 Feb 2024 16:00 | -0.18 | 0.44 | +344.3% | Beat |
| 02 Nov 2023 16:00 | -0.70 | -0.58 | +17.3% | Beat |
| 03 Aug 2023 16:00 | -0.66 | -0.68 | -3.7% | Miss |
| 04 May 2023 16:00 | -0.70 | -0.67 | +4.3% | Beat |
| 15 Mar 2023 16:00 | -0.61 | -0.69 | -13.0% | Miss |
| 08 Nov 2022 16:00 | -0.85 | -0.64 | +24.4% | Beat |
| 04 Aug 2022 16:00 | -0.98 | -0.84 | +14.3% | Beat |
| 04 May 2022 17:00 | -0.60 | -0.43 | +27.9% | Beat |
| 28 Feb 2022 16:00 | -0.76 | -0.77 | -1.2% | Miss |
| 03 Nov 2021 17:00 | -0.66 | -0.70 | -5.7% | Miss |
| 04 Aug 2021 16:00 | -0.53 | -0.69 | -30.3% | Miss |
| 04 May 2021 16:00 | -0.56 | -0.54 | +4.4% | Beat |
| 10 Mar 2021 16:00 | -0.47 | -0.48 | -1.5% | Miss |
| 04 Nov 2020 17:00 | -0.56 | -0.21 | +62.5% | Beat |
| 06 Aug 2020 16:00 | -0.58 | -0.57 | +1.8% | Beat |
| 07 May 2020 17:00 | -0.68 | -0.72 | -6.4% | Miss |
| 10 Mar 2020 16:00 | -0.70 | -0.63 | +10.0% | Beat |
| 06 Nov 2019 16:00 | -0.73 | -0.61 | +16.1% | Beat |
| 07 Aug 2019 07:00 | -0.27 | -1.18 | -331.7% | Miss |
| 08 May 2019 07:00 | -0.63 | -0.58 | +8.4% | Beat |
| 12 Mar 2019 16:00 | -0.47 | -0.57 | -20.3% | Miss |
| 06 Nov 2018 16:00 | -0.33 | -0.38 | -15.2% | Miss |
| 07 Aug 2018 16:00 | -0.29 | -0.41 | -43.0% | Miss |
| 09 May 2018 16:00 | -0.24 | -0.36 | -50.0% | Miss |
| 07 Mar 2018 16:00 | -0.37 | -0.15 | +59.5% | Beat |
| 06 Nov 2017 16:00 | -0.61 | -0.29 | +52.2% | Beat |
| 08 Aug 2017 16:00 | -0.81 | -0.89 | -9.9% | Miss |
| 10 May 2017 16:00 | -0.59 | -0.84 | -41.2% | Miss |
| 07 Mar 2017 16:00 | -0.49 | -0.67 | -35.4% | Miss |
| 14 Nov 2016 16:00 | -0.64 | -0.87 | -34.9% | Miss |
| 15 Sep 2016 16:00 | -0.94 | -0.44 | +52.9% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 46M | -89.4% | -130.1M | -282.8% | -2.05 | -148.5% | 56.1M |
| 2024 | 434.4M | +624.1% | 275.2M | 63.3% | 4.23 | +404.3% | 182.8M |
| 2023 | 60M | +125.7% | -79M | -131.6% | -1.39 | +46.5% | -70.8M |
| 2022 | 26.6M | — | -127.4M | -479.3% | -2.60 | — | -108.9M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 134.16 | 138.82 | 131.26 | 134.38 | -0.36% | 542,887 | |
| 11 Nov 2026 | 136.51 | 136.98 | 132.03 | 134.86 | -1.03% | 332,600 | |
| 10 Nov 2026 | 134.21 | 137.97 | 133.35 | 136.26 | +0.26% | 528,500 | |
| 09 Nov 2026 | 135.01 | 137.93 | 131.31 | 135.90 | +2.92% | 607,100 | |
| 06 Nov 2026 | 135.26 | 138.40 | 128.00 | 132.04 | -2.38% | 972,900 | |
| 05 Nov 2026 | 142.56 | 143.30 | 134.39 | 135.26 | -5.66% | 582,600 | |
| 04 Nov 2026 | 145.61 | 145.61 | 138.39 | 143.37 | +2.23% | 777,200 | |
| 03 Nov 2026 | 140.73 | 144.26 | 139.91 | 140.24 | +0.62% | 673,200 | |
| 02 Nov 2026 | 145.74 | 146.01 | 139.35 | 139.37 | -3.78% | 486,500 | |
| 30 Oct 2026 | 144.34 | 146.00 | 142.54 | 144.85 | +0.35% | 322,600 | |
| 1,250 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Protagonist Therapeutics (PTGX) Stock Looks Priced At A Premium As Its 7x Three Year Run Continues (opens in a new tab) Simply Wall St. · 06 Nov 2026 17:15
- HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221 (opens in a new tab) Benzinga · 06 Nov 2026 16:12
- Earnings Beat Might Change The Case For Investing In Protagonist Therapeutics Stock (opens in a new tab) Simply Wall St. · 06 Nov 2026 12:17
- Protagonist Therapeutics (PTGX) Swung To Profit, Is It A Bargain Or Fully Priced? (opens in a new tab) Simply Wall St. · 06 Nov 2026 11:13
- Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass Estimates (opens in a new tab) Zacks · 05 Nov 2026 21:45
- Protagonist Therapeutics: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 05 Nov 2026 21:22
- Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update (opens in a new tab) 05 Nov 2026 21:05
- Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth (opens in a new tab) Zacks · 29 Oct 2026 13:00
- Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? (opens in a new tab) Zacks · 28 Oct 2026 12:55
- Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know (opens in a new tab) Zacks · 15 Oct 2026 16:00
- Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status (opens in a new tab) Insider Monkey · 06 Sep 2026 13:55
- MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model? (opens in a new tab) Insider Monkey · 04 Sep 2026 17:14
- Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News (opens in a new tab) Simply Wall St. · 02 Sep 2026 00:07
- The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones (opens in a new tab) Simply Wall St. · 01 Sep 2026 13:14
- Protagonist Therapeutics (PTGX) Could Be 63% Below Fair Value After Investor Update Call (opens in a new tab) Simply Wall St. · 01 Sep 2026 09:13
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 134.86 USD
- Market cap
- 9.0B
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow PTGX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.